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Abstract
Purposes: 1. To determine the optimal pelvic nodal clinical target volume for post-operative treatment of
endometrial cancer. 2. To compare the DVH of different treatment planning techniques applied to this new CTV
and the surrounding tissues.
Methods and Materials: Based on the literature, we selected a methodology to delineate nodal target volume to
define a NEW-CTV and NEW-PTV. Conventional 2D fields, 3D fields based on anatomic guidelines per RTOG 0418,
3D fields based on our guidelines, and IMRT based on our guidelines were assessed for coverage of NEW-CTV,
NEW-PTV, and surrounding structures. CT scans of 10 patients with gynecologic malignancies after TAH/BSO were
used. DVHs were compared.
Results: For NEW-PTV, mean V45Gy were 50% and 69% for 2D and RTOG 0418-3DCRT vs. 98% and 97% for NEW-
3DCRT and NEW-IMRT (p < 0.0009). Mean V45Gy small bowel were 24% and 20% for 2D and RTOG 0418-3DCRT,
increased to 32% with NEW-3DCRT, and decreased to 14% with IMRT (p = 0.005, 0.138, 0.002). Mean V45Gy rectum
were 26%, 35%, and 52% for 2D, RTOG 0418-3DCRT, and NEW-3DCRT, and decreased to 26% with NEW-IMRT (p <
0.05). Mean V45Gy bladder were 83%, 51%, and 73% for 2D, RTOG 0418-3DCRT, and NEW-3DCRT, and decreased to
30% with NEW-IMRT (p < 0.002).
Conclusions: Conventional 2D and RTOG 0418-based 3DCRT plans cover only a fraction of our comprehensive
PTV. A 3DCRT plan covers this PTV with high doses to normal tissues, whereas IMRT covers the PTV while
delivering lower normal tissue doses. Re-consideration of what specifically the pelvic target encompasses is
warranted.
Background
W h o l ep e l v i cr a d i a t i o nt h erapy (WPRT) is commonly
used in the post-operative treatment of endometrial
malignancies as adjuvant therapy targeting the pelvic
lymph nodes, in addition to the vaginal apex. Conven-
tional pelvic fields reference anatomical structures of the
bones to establish the pelvic radiation therapy fields.
Data from studies including lymphangiograms, intra-
operative measurements, or placed surgical clips have
found that radiation fields determined by bony land-
marks alone results in suboptimal coverage of the nodal
areas [1-4]. With routine use of CT simulation, contour-
ing vessels on the CT image is used as surrogate for
lymph node localization. This method provides more
complete, precise, and individualized field delineation
compared to that achieved when using conventional pel-
vic fields[5]. Nevertheless, attempting to do this raises
several issues that were heretofore not addressed.
Specifically, it is undefined exactly which nodal
regions are the targets for post-operative treatment of
endometrial cancer. We undertook a review of the
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We then used these data to define our pelvic nodal
CTV and PTV. We then applied conventional, 3D con-
formal, and IMRT techniques to compare the ability of
these techniques to cover this nodal CTV and to deter-
mine the normal tissue dosimetric consequences.
Methods
Definition of target structures and subsequent planning
We comprehensively reviewed the literature for articles
that identified the locations of the pelvic lymph nodes
rather than assuming a location. Once the papers were
identified, the information from these papers was used
to define new CTVs and PTVs. We then planned treat-
ments and determined the dosimetric coverage of these
new CTVs and PTVs and the surrounding normal struc-
tures. We planned using four different methods: 1)Con-
ventional, 2) 3D-conformal as defined by RTOG 0418,
3) 3D-conformal based on these newly defined CTVs
and PTVs, and 4) IMRT based on these new CTVs and
PTVs. The treatment planning system used was Pinna-
cle
3 Version 6.2b. For IMRT, the dose calculation algo-
rithm is the Collapsed Cone Convolution Superposition
dose algorithm. 18 MV photons were used.
Patient selection
The CT scans of 10 consecutive patients from our insti-
tution with gynecologic malignancies who have under-
gone TAH/BSO with or without pelvic and para-aortic
lymph node dissections were obtained under an IRB-
approved protocol.
Statistical Analysis
The paired-samples test was used to compare dose
received to the target volumes and normal structures
among the different plans.
Results
Literature review
We found three papers that defined the location of the
lymph nodes from the vessels. In the paper by Portaluri
et al., an extensive analysis of nodal location was per-
formed[6]. However, the patients analyzed in this study
had advanced disease and a variety of malignancies.
Thus, these data may not be an ideal source for locating
clinically uninvolved pelvic nodes in patients with gyne-
cologic malignancies. Taylor et al., however, specifically
located the unenlarged nodes in gynecologic patients
using ultrasmall superparamagnetic iron oxide particle
infusion prior to MRI[7]. This paper, however, did not
address the cranial and caudal borders of the relevant
lymph nodes. The paper by Shih et al. also addressed
the locations of the pelvic nodes using the iron oxide
infusion with pelvic MRI in a series of prostate cancer
patients[8]. Besides addressing the radial distance from
the pelvic vessels this analysis also assessed the cranial
and caudal extent. We combined these two sources,
with some minor modifications, in defining our lymph
node CTVs as is detailed below. Of note, the Taylor
group has recently validated their recommendations on
another cohort, further strengthening their recommen-
dations[9]. Another recently published paper using this
method has similar recommendations[10].The different
definitions of the pelvic nodal CTVs are summarized in
Table 1.
Definition of Clinical Target Volumes
Common iliac nodes
7-mm margin uniformly surrounding the common iliac
vessels, extending posterolaterally to the psoas muscle
and vertebral body (Figure 1a). The superior extent
begins at the distal 2.5 cm of these vessels.
Internal iliac nodes
5-mm margin uniformly surrounding the internal iliac
vessels, extending laterally to the pelvic sidewall (Figure
1b). Although the Taylor group recommended a 7-mm
margin around the vessels, their data showed that a 5-
mm margin covered 93.8% of lymph nodes (vs. 98.6%
with 7-mm), so we used the smaller margin in our study
[7]. The inferior extent reaches 8 cm below the bifurca-
tion of the common iliac into the internal iliac vessels
External iliac nodes
7-mm margin uniformly around external iliac vessels,
extending anteriorly along the ilopsoas muscle by
another 10 mm (a total of 17 mm from the vessel) (Fig-
ure 1c). The inferior extent reaches 8 cm below the bifur-
cation of the common iliac into the external iliac vessels.
Obturator nodes
15-mm margin joining corresponding medial and lateral
borders of internal and external iliac contours, creating
as i n g l ev o l u m eo ne a c hs i d eo ft h ep e l v i s( F i g u r e1 d ) .
Although the Taylor group recommended an 18-mm
margin joining the internal and external iliac contours
contours, their data showed that a 15-mm margin
covered 95% of lymph nodes (vs. 99% with 18-mm), so
we used the smaller margin in our study[7].
The upper 3 cm of vagina (which was identified by the
installation of contrast) was contoured as CTV. The
combined volumes for all nodal regions specified above
and the upper vagina is termed NEW-CTV. All CTV
expansions above were modified to exclude bowel and
bone.
Planning Target Volume
T h ep l a n n i n gt a r g e tv o l u m eb a s e do nt h eN E W - C T Vi s
termed NEW-PTV and is defined as 7 mm around the
NEW-CTV and 10 mm around the upper 3 cm of
vagina.
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The rectum was delineated from the anal margin to the
sigmoid flexure, and the entire bladder was contoured.
The small and large bowels were contoured on all slices
until 2 cm superior to the CTV. Small bowel and large
bowel were contoured separately. Oral contrast was
used for delineation of small bowel.
Plans
Four types of radiation plans were generated for each
patient:
1) 2D - 2D fields as done in Finlay et al. (with the
addition of corner blocks) i.e. four fields with the bor-
ders of the fields extending from the L5-S1 interspace
to the bottom of the obturator foramen, and the front
of the pubic symphysis to the S2-S3 interspace with
standard blocking (Figure 2a and 2b).
2) RTOG 0418-3DCRT - the nodes at risk and upper
3 cm of vagina were contoured as per RTOG 0418
guidelines[11]. 7 mm was added to the vessels and 10
mm were added to the vagina to create the CTV. Four
fields were used with the block edges 5 mm beyond the
CTV to account for the penumbra. The superior extent
of the CTV was 7 mm below L5-S1. The inferior extent
of the CTV was limited so that the CTV ended at the
top of the femoral heads (Figure 2c and 2d).
3) NEW-3DCRT - Four field 3D plan with the CTV as
the newly defined nodal volumes based on literature
review above (Figure 2e and 2f)
4) NEW-IMRT - Seven field IMRT plan based on
same volumes as in 3. The IMRT parameters were as
follows: In addition to the PTV, two control structures
were created. The first control structure is a 2 cm “ring”
( t e r m e dR I N G )w h i c hi sc r e a t e da r o u n dt h eP T V .T h e
Table 1 Various Guidelines for Pelvic Node CTV Drawing
Common Iliac External Iliac Internal Iliac Obturator
Portaluri* Cranial: Aortic bifurcation Cranial: Common iliac bifurcation (L5-S1) Cranial: Common iliac
bifurcation (L5-S1)
Cranial: Cranial sections
of obturator muscle
Caudal: Common iliac
bifurcation
Caudal: Femoral ring (disappearance of
lateral muscles of abdominal wall, artery
becomes lateral)
Caudal: Cranial sections of
coccygeal muscle
Caudal: Superior margin
inferior branch of pubic
bone
Anterior: Mesocolon Anterior: Fat of small bowel, deferent duct or
round ligament
Anterior: Bladder, uterus Anterior: External iliac
vein
Lateral: Psoas muscles Lateral: Lateral: Lateral:
Posterior: sacrum - Cranial: Psoas, int iliac vein, iliac bone,
sacroiliac joint
- Cranial: Psoas muscle,
int iliac vein, iliac bone,
sacroiliac joint
- Cranial:
Acetabulum
- Caudal : Piriformis m., internal
obturatorius m.
- Caudal : Piriformis m.,
int obturatorius m.
- Caudal: Internal
obturator muscle
Posterior: Posterior: Posterior: Internal
obturator muscle
- Cranial: Ext iliac v - Cranial: Sacral wing Medial: Bladder
- Caudal: Pubic bone (superior branch) - Caudal: Piriform
muscle
Medial: Mesocolon, uterus, bladder Medial: Mesocolon, uterus,
bladder
Taylor† 7 mm around common iliac
vessels, extending posterior and
lateral borders to psoas and
vertebral body
7 mm around ext iliac vessels, extending
anterior border by additional 10 mm
anterolaterally along ilopsoas muscle to
include lateral external iliac nodes
7-mm margin around int
iliac vessels, extending
lateral borders to pelvic
sidewall
18-mm wide strip along
pelvic sidewall joining
external and internal
iliac regions
Shih†† 2.0 cm expansion around the
distal 2.5 cm of common iliac
vessels superior to bifurcation
2.0 cm expansion around ext iliac vessels for
9 cm from common iliac bifurcation
2.0 cm expansion around int
iliac vessels for 8.5 cm
extending from common
iliac bifurcation
Not specified
RTOG
0418||
7 mm around common iliac
vessels, with superior border at
7 mm below L4-L5 interspace
7 mm around ext iliac vessels, terminating at
level of femoral head
7 mm around int iliac
vessels
Not specified
* Portaluri M BS, Perez C, et al. A three-dimensional definition of nodal spaces on the basis of CT images showing enlarged nodes for pelvic radiotherapy. Int J
Radiat Oncol Biol Phys 2005;63:1101-1107.
† Taylor A RA, Reznek RH, et al. Mapping pelvic lymph nodes: Guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys
2005;63:1604-1612.
†† Shih HA HM, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation
based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 2005;63:1262-1269.
|| Jhingren A, Winter K, Portelance L. A phase II study of intensity modulated radiation therapy (IMRT) to the pelvic for post-operative patients with endometrial
carcinoma (RTOG 0418). Int J Radiat Oncol Biol Phys 2008; 72:S16-S17
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passes all tissue beyond the RING. (This structure is
called OUTER-RING,PTV.) The PTV had UNIFORM
dose objective of 4500 cGy with 100% weighting. The
RING had MAXIMUM DOSE objective of 4450 cGy to
1% of volume with 100% weighting. The OUTER-RING,
PTV had a MAXIMUM DOSE objective of 2250 cGy to
1% of volume with 100% weighting.
Dosimetry (Table 2)
Both the 2D and RTOG 0418-3DCRT plans covered
only a fraction of the NEW-PTV. The NEW-PTV mean
V45Gy were 50% and 69% for 2D and RTOG 0418-
3DCRT (p < 0.0009 both, compared to NEW-IMRT)
compared to 98% and 97% for the NEW-3D and the
NEW-IMRT plans, respectively.
Part of the reason for this was incomplete coverage of
the distal 2.5 cm of the common iliac nodes which
should be included in the CTV based on Shih et al[8].
The superior border of the RTOG 0418-3DCRT plan
was defined as L4-L5. With this border, 5/10 patients
had 100% coverage of the distal 2.5 cm of common iliac
vessels, 1/10 patients had 0% coverage, and 4/10 patients
had partial coverage (36%, 48%, 60%, and 84%). When
this border was placed at L5-S1 as is sometimes done in
clinical practice, 9/10 patients had 0% coverage and 1/
10 patients had partial coverage (25%).
Mean V45Gy for small bowel was 24% for 2D and
20% for RTOG 0418-3DCRT. To cover NEW-PTV with
3D planning (i.e. NEW-3DCRT), the mean small bowel
V45Gy increased to 32% (p = 0.006 vs. 2D and < 0.0009
v s .R T O G0 4 1 8 - 3 D C R T ) .H o w e v e r ,N E W - I M R T
decreased this to 14% while still covering the NEW-PTV
(p = 0.005, p = 0.138 and p = 0.002 for 2D, RTOG
0418-3DCRT and NEW-3DCRT, respectively, vs. NEW-
IMRT).
Figure 1 Defining the NEW-CTV. a. Common iliac nodes: 7 mm margin around common iliac vessels, extending posterolaterally to the psoas
muscle and vertebral body b. Internal iliac nodes: 5 mm margin around internal iliac vessels, extending laterally to pelvic sidewall c. External iliac
nodes: 7 mm around external iliac vessels, extending anteriorly along the iliopsoas muscle by additional 10 mm d. Obturator nodes: 15 mm
margin joining corresponding medial and lateral borders of internal and external iliac contours. Red: Vessels; Orange: CTV expansion; Cyan: PTV
expansion
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0418-3DCRT and NEW-3DCRT increased mean rectal
V45Gy to 35% and 52%, respectively (both p = NS com-
pared to 2D). NEW-IMRT was able to decrease mean
rectal V45Gy back to 26% (p = 0.002 and 0.016 com-
pared with RTOG 0418-3DCRT and NEW-3DCRT,
respectively). For the bladder, mean V45Gy for 2D and
RTOG 0418-3DCRT were 83% and 51% (p = 0.049).
The NEW-3DCRT mean bladder V45Gy is 73% (p = NS
v s .2 Da n dR T O G - 3 D C R T ) ,b u tN E W - I M R Tw a sa b l e
to decrease this to 30% (all p < 0.002).
Discussion
Our study had three goals. Our first goal was to com-
prehensively review the literature and define pelvic
nodal region clinical target volumes and planning target
volumes. In our opinion, the ultrasmall superparamag-
netic iron oxide particle infusion prior to MRI method,
as used by Taylor et al. and Shih et al., is superior to all
others for determining the location of these clinically
uninvolved nodes[7,8]. However, developing a compre-
hensive definition of the target volumes using this tech-
nique in all dimensions (cranial, caudal, and radial) has
Figure 2 Comparison of 2D, RTOG 0418-3DCRT, and NEW-3DCRT plans for one patient. AP and lateral views of 2D plan (a,b) AP and
lateral views of RTOG 0418-3DCRT plan (c,d) AP and lateral views of NEW-3DCRT plan (e,f)
Table 2 Mean V45Gy Coverage of Target and Normal
Structures among Different Plans
2D RTOG 0418-
3DCRT
NEW-
3DCRT
NEW-
IMRT
NEW-PTV 50% 69% 98% 97%
(p <
0.0009)
(p < 0.0009) (p = NS)
Small
Bowel
24% 20% 32% 14%
(p = 0.019) (p < 0.0009) (p < 0.0009)
Rectum 26% 35% 52% 26%
(p = NS) (p = 0.002) (p = 0.016)
Bladder 83% 51% 73% 30%
(p = NS) (p = NS) (p < 0.0009)
Definitions: 2D -four fields with borders extending from the L5-S1 interspace
to the bottom of the obturator foramen, and the front of the pubic symphysis
to the S2-S3 interspace with standard blocking. RTOG 0418-3DCRT - the nodes
at risk and upper 3 cm of vagina contoured as per RTOG 0418 guidelines,
with 7 mm added to the vessels and 10 mm to the vagina to create the CTV.
Four fields were used with the block edges 5 mm beyond the CTV to account
for the penumbra. Superior extent of the CTV was 7 mm below L5-S1. Inferior
extent of CTV was limited so that the CTV ended at the top of the femoral
heads. NEW-3DCRT - Four field 3D plan with the CTV based on our newly
defined nodal volumes. NEW-IMRT - Seven field IMRT plan with the CTV based
our newly defined nodal volumes.
All of the V45Gy reported were mean values from the 10 patients analyzed.
P values reported were from comparison against the NEW-IMRT plan.
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mine the cranial and caudal extent of the nodes at risk
which in our view is an important unaddressed issue.
The results of Shih et al. provide this information. Con-
versely, Shih at al. do not provide circumferential
volumes needed to create CTVs with the same level of
detail as provided by Taylor et al. Therefore, we recom-
mend a combination of the two as the optimal method
to create accurate CTVs and PTVs.
Our second goal was to test the dosimetric implica-
tions of adopting these detailed recommendations for
target definition of different nodal CTV groups pro-
posed by Taylor et al and Shih et al. Our analysis shows
that complete coverage of the nodes at risk is not
achieved with current treatment techniques. Further-
more, any attempt to do this with 2D or 3D-CRT tech-
niques would result in significantly higher doses to the
rectum and small bowel which would likely increase the
complication rates. However, we have shown that using
IMRT, the nodes at risk can be completely covered
while actually decreasing the doses to the surrounding
normal tissues compared with current standards of care.
This would be expected to actually decrease the compli-
cations of pelvic radiotherapy compared with standard
treatment.
Our findings are consistent with other dosimetric stu-
dies that compared IMRT to standard 2D and 3DCRT
plans, although these studies defined the CTV differ-
ently[12-14]. Portelance et al reported a 48-67% reduc-
tion in volume of small bowel irradiated to more than
45 Gy with IMRT vs. standard 2D plan[14]. Roeske et al
reported a 50% reduction in volume of small bowel irra-
diated to more than 45 Gy with IMRT vs. standard
3DCRT[12]. Our results showed a 42% reduction in
volume of small bowel irradiated to 45 Gy with IMRT
(designed to comprehensively irradiate the pelvis as pro-
posed in this study) compared with a standard 2D plan,
and a 30% reduction in volume of small bowel irradiated
to 45 Gy with IMRT compared with a 3DCRT plan that
defined the CTV based on the small volumes recom-
mended in RTOG-0418.
Our third goal was to assess the reasons for these
dosimetric differences and to consider the clinical rele-
vance of our observations. The differences in CTV cov-
erage between the different methods is due in large part
to three issues: 1) the cranial extent of the target com-
mon iliac nodes 2) the caudal extent of the target exter-
nal iliac nodes and 3) the need (and, if needed, the
extent) to treat the internal iliac nodes. The external
iliac lymph nodes are an acknowledged target, but the
caudal extent of coverage of a typical radiotherapy port
does not cover the caudal extent of this nodal chain.
Similarly, the common iliac nodes are often a stated tar-
get and yet a variable cranial extent of these nodes is
encompassed in a typical pelvic field that sets the super-
ior border at L4-L5 or L5-S1, as is commonly done.
Similarly, what portion, if any, of the internal iliac
lymph nodes should be included in the defined target is
not well-defined.
While our analysis provides a rational method for
determining the target nodal structures, it suggests
that a larger treatment field is required to encompass
all the intended nodal stations that should be included
as described in the historic literature. It should be
acknowledged that excellent outcome data using con-
ventional pelvic fields are reported in the published lit-
erature. For example, the PORTEC trial showed five-
year locoregional recurrence rates of only 4% in those
randomized to post-operative pelvic radiotherapy[15].
Postoperative radiotherapy in this trial was delivered
using a conventional technique with a superior border
at L5-S1 via a three-field or a four-field box. In addi-
tion, the recent MRC/NCIC trial of patients with
intermediate-risk or high-risk early-stage endometrial
cancer randomized to surgery with and without pelvic
radiation therapy showed 5-year cumulate incidence of
isolated vaginal or pelvic recurrence was only 2.9% in
those randomized to post-operative radiotherapy[16].
The actuarial total pelvic failure rate is not given.
However, the crude number of isolated pelvic recur-
rences is 13 and the total number of pelvic recur-
rences is 20; so the actuarial total pelvic recurrence
rate in those who received post-operative conventional
pelvic radiotherapy is about 4.5%. No information was
reported regarding the treatment fields in their analy-
sis but it is likely that conventional techniques were
used.
These low recurrence rates suggest that it may not
be necessary treat as extensive a volume as we suggest
here. Specifically, since the outcome is so good even
though the common and internal iliac nodes are par-
tially and variably covered in conventional treatment, a
reasonable conclusion would be that treatment of
these nodal regions is not needed in the typical node
negative, high risk, endometrial cancer patient receiv-
ing post-operative pelvic radiotherapy. Further studies
on patterns of failure would be valuable to address this
question. In the absence of data from a pattern of fail-
ure analysis suggesting otherwise, a reasonable
approach would be to exclude the common and inter-
nal iliac nodal regions from the target structures. This
might also allow treatment of smaller treatment
volumes and thereby potentially decrease complica-
tions while maintaining the excellent results of conven-
tional treatment. A prospective evaluation of this
approach is recommended to determine the efficacy
and morbidity of this approach and we hope to under-
take such a study.
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The nodal tissue at risk can be defined based on a com-
bination of data from Taylor et al and Shih et al[7,8].
Treating these tissues in their entirety would result in
significant increases in dose to normal tissues if conven-
tional or 3D techniques are used. The use of IMRT
would further decrease the dose to acceptable thresh-
olds. In light of the very good results with conventional
treatment which does not treat all the stated nodal tar-
gets, further work is needed to define the ideal target
lymph node stations when the primary tumor has high
risk factors but the nodes are pathologically negative.
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